ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Osmotic Demyelination Syndrome after Liver Transplantation- Etiology and Treatment Options

P. Mihaylov1, D. Soma2, D. Kuruppu2, B. Ekser2, R. Mangus2, J. Fridell2, R. Snook2, C. Kubal2

1Indiana Univ School of Medicine, Pavia University School of Medicine, Indianapolis, IN, 2Indiana Univ School of Medicine, Indianapolis, IN

Meeting: 2019 American Transplant Congress

Abstract number: B323

Keywords: Liver transplantation, Plasmapheresis, Post-operative complications, Prognosis

Session Information

Session Name: Poster Session B: Liver Retransplantation and Other Complications

Session Type: Poster Session

Date: Sunday, June 2, 2019

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall C & D

*Purpose: Orthotopic liver transplantation (OLT) is the only effective therapy for patients with end stage liver failure that increases long-term survival, but is not without complications. One rare and devastating complication is osmotic demyelination syndrome (ODS). The purpose of this study is to evaluate the plasmapheresis (PLEX) as a treatment option in patients with ODS after liver transplantation.

*Methods: Charts for all patients undergoing OLT at our center between January 2007 and March 2017 (n=1140) were retrospectively reviewed. From this data, 146 patients underwent neurological work up for postoperative neurological changes.

*Results: Of these, nine patients were diagnosed with ODS based on clinical symptoms and brain MRI findings. The leading indication for neurological consultation was altered mental status. Other symptoms included: dysarthria, dysphagia, difficulty with tongue movements, increased tone, weakness of extremities, tremor, myoclonus, ataxia, pseudobulbar affect, frontal release signs, hallucinations, and seizures. Five of these nine patients were treated with plasmapheresis and none received intravenous immunoglobulin. Neurological evaluation was done with MRI head, EEG and Kurtzke’s Expanded Disability Status Scale (EDSS) score prior to discharge and upon follow-up. The median follow up was 465 days. Data gathered from the electronic medical record included age at time of OLT, gender, indication for OLT, diagnosis of alcoholic cirrhosis, presence of pre-transplant encephalopathy, operative time, blood loss during operation, amount of blood product and IVF transfusion, requirement of postoperative dialysis or continuous veno-venous hemodialysis (CVVH), pre-transplant sodium level, post-transplant sodium level, other electrolyte fluctuations within 48 hours of the postoperative period, and tacrolimus peak levels within the first fourteen days of surgery. All analyzes has been done by non-parametric analysis. The only predictor for ODS is the intraoperative blood loss (Tab 1). The plasmapheresis group had significantly better EDSS score and their EDSS score had improved significantly during the hospital stay (Fig 1).

*Conclusions: ODS is a rare and potentially devastating complication after OLT. It requires a high degree of clinical suspicion. It is important to monitor several factors in patients undergoing liver transplant, these include pre-operative and post-operative sodium levels as well as administration of blood products. The only valid treatment is early plasmapheresis, which have been shown to improve the patient’s neurological status and outcomes.

 border=

ODS factors
Factor p-value
Operative time 0.364
Blood loss 0.047
Delta sodium 0.117
Delta chloride 0.118
Tacrolimus peak 0.897
Pre-transplant phosphorus level 0.064
Age at time of OLT 0.068
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Mihaylov P, Soma D, Kuruppu D, Ekser B, Mangus R, Fridell J, Snook R, Kubal C. Osmotic Demyelination Syndrome after Liver Transplantation- Etiology and Treatment Options [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/osmotic-demyelination-syndrome-after-liver-transplantation-etiology-and-treatment-options/. Accessed May 18, 2025.

« Back to 2019 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences